

October 9, 2020

Total Joint Orthopedics, Inc. Chris Weaber Director of Research and Development 1567 E. Stratford Avenue Salt Lake City, Utah 84106

Re: K202740

Trade/Device Name: Klassic® Knee System Tibial Inserts, PS-Max®

Regulation Number: 21 CFR 888.3560

Regulation Name: Knee Joint Patellofemorotibial Polymer/Metal/Polymer Semi-Constrained Cemented

Prosthesis

Regulatory Class: Class II Product Code: JWH, MBH Dated: September 18, 2020 Received: September 18, 2020

Dear Chris Weaber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

K202740 - Chris Weaber Page 2

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Ting Song, Ph.D., R.A.C.
Acting Assistant Director
DHT6A: Division of Joint
Arthroplasty Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

• Correctable varus-valgus deformity and moderate flexion contracture

Revision of a previously failed knee arthroplasty
Patients who require a total knee replacement

Form Approved: OMB No. 0910-0120

Expiration Date: 06/20/2020 See PRA Statement below.

k) Number (if known)	
2740	
ce Name	_
sic® Knee System Tibial Inserts, PS-Max	
cations for Use (Describe)	
Klassic® Knee System is intended for prosthetic replacement in treatment of the following:	
tient conditions of non-inflammatory degenerative joint disease (NIDJD): avascular necrosis and osteoarthritis	
tient conditions of inflammatory joint disease (IJD): rheumatoid arthritis	
tients with failed previous surgery where pain, deformity, or dysfunction persists	

The Klassic® Knee System is indicated for cemented use only, except for the Klassic® Femur with Cobalt 3D®, and the Klassic® Tibial Baseplate with Ti-Coat® which are indicated for cementless use.

Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

TJO Klassic® Knee System – Special 510(k)

510(k) Summary

Manufacturer: Total Joint Orthopedics, Inc.

1567 E. Stratford Avenue Salt Lake City, UT 84106 Phone: 801.486.6070 Fax: 801.486.6117

Contact: Mr. Chris Weaber

Director of Research and Development

Prepared By: MCRA, LLC

1050 K Street, NW, Suite 1000

Washington, DC 20001 Phone: 202.552.5800

Date Prepared: September 18, 2020

Device Trade Name: Klassic[®] Knee System Tibial Inserts, PS-Max[®]

Device Common Name: PS Inserts

Classification: 21 CFR 888.3560 – Knee joint patellofemorotibial

polymer/metal/polymer semi-constrained cemented

21 CFR 888.3565 Knee joint patellofemorotibial metal/polymer

porous-coated uncemented prosthesis

Class II

Product Codes: JWH, MBH

Indications for Use:

The Klassic[®] Knee System is intended for prosthetic replacement in treatment of the following:

- Patient conditions of non-inflammatory degenerative joint disease (NIDJD): avascular necrosis and osteoarthritis
- Patient conditions of inflammatory joint disease (IJD): rheumatoid arthritis
- Patients with failed previous surgery where pain, deformity, or dysfunction persists
- Correctable varus-valgus deformity and moderate flexion contracture
- Revision of a previously failed knee arthroplasty
- Patients who require a total knee replacement

The Klassic[®] Knee System is indicated for cemented use only, except for the Klassic[®] Femur with Cobalt 3D[®], and the Klassic[®] Tibial Baseplate with Ti-Coat[®], which are indicated for cementless use.

Device Description:

The purpose of this Special 510(k) is to add the Klassic[®] Tibial Inserts, PS-Max[®], an additional posterior stabilizing design option, to the Klassic[®] Knee System (K112906). The Klassic[®] Tibial Inserts, PS-Max[®] are available in various sizes and thicknesses to match patient anatomy and provide surgical options.

Predicate Devices:

The Klassic® Tibial Inserts, PS-Max®, are substantially equivalent to the predicate Klassic® Tibial Inserts, PS-Post™ (K183596) with respect to intended use, design, material, method of fixation and function. The information summarized in the Design Control Activities Summary demonstrates that the subject Klassic® Tibial Inserts, PS-Max®, met the pre-determined acceptance criteria for the verification activities.

Substantial Equivalence:

Bench testing and engineering analysis were performed for the subject Klassic[®] Tibial Inserts, PS-Max[®], to evaluate Femoral/Tibial Stability Characteristics and Contact Stress Evaluation, Range of Motion, Knee Simulator Wear, Tibial Insert Post Strength and Fatigue and Tibial Insert Modular Disassembly. The results of analysis and testing indicate that the subject tibial inserts are substantially equivalent to the predicate components. Additionally, the subject components are in compliance with LAL requirements for orthopedic implants.